• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

How do we stop the corporatization of medicine?


Private equity firms and insurance companies are encroaching on health care

Blocks with 'private equity' text ©wladimir1804-stock.adobe.com


Private equity (PE) wants to take over physician practice, just as hospitals wanted to do in the 1990s (and then again in the 2010s). Not content to be marginalized, insurance companies want to own you, too.

If you want to practice medicine outside of academia, here are your four primary choices:

  1. Traditional private practice;
  2. Hospital-owned practice;
  3. PE-owned practice; and
  4. Insurance company-owned practice.

Today, more than 7 in 10 doctors work for someone other than themselves. The number is growing. With hospitals no longer buying out doctors at their former clip, PE firms and insurance companies have taken up the slack with increasing speed.

To wit: in more than 1 in 4 metropolitan statistical areas (MSAs), more than 30% of the physicians work for a single PE firm. And in 13% of MSAs, a single PE firm controls more than 50% of the doctors. This PE firm may trade under different names depending upon the specialty, but the specialty-specific PEs are part and parcel of a larger PE firm.

To wit, two: Optum, a United Healthcare subsidiary, employs more than 70,000 doctors to practice medicine (as opposed to denying care). That’s about one of every 16 doctors in the United States working for the insurance company that insures between 12% and 15% of all Americans. If you don’t work for Optum/United, odds are you will be out of their networks when they hire others in your specialty in your market. United is famous for its narrow networks.

(Here it may be instructive—or at least therapeutic for me—to share a story. I co-own Infusion Solutions, an infusion center in Richmond, VA. Infusion Solutions opened in 2020. All insurance companies, save United Healthcare and its narrow networks, welcomed us as a less expensive alternative to hospital infusion centers. United said no thanks to repeated entreaties.

Fast forward to early 2021, when 3,800 Americans were dying daily from COVID, and monoclonal antibodies became available to the general public. With area hospitals overwhelmed with caring for the acutely ill, Infusion Solutions became the primary monoclonal antibody treatment center for Central Virginia.

I went back to United with a simple ask: ‘Let’s save some lives together. Let us help your COVID insureds, and I will never ask to participate in your networks.’ United said no.)

Thank you for indulging me with that “can’t make this stuff up” digression. Let’s get back to the task at hand.

This ‘land grab’ by insurance companies and PE firms has caught the attention of the antitrust regulators. Why? Money. Market concentration and higher prices go hand-in-hand.

Here’s an example from the world of gastroenterology. Let’s say you have an appointment with your gastroenterologist. If your GI is in private practice, the average price of your visit will be just shy of $250, or about 15% higher than it was a decade ago. But if your GI is part of a PE conglomerate, the average price of your visit will be about $320. You, the patient, are paying almost $70 more by going to a PE GI.

If you’re the PE gastroenterologist, that’s good (provided a big part of the delta goes to you). But if you’re the patient, it’s bad. You’re paying a lot more for the same care because your doctor ‘sold out.’ I am not trying to be crass but I believe it’s important that you understand how many patients see it. You need to be able to explain to your patients, legislators, and perhaps the local newspaper how your decision to sell your practice was done for the ‘right’ reasons.

Regulators get it: PE firms and insurance companies are buying practices to make money for their investors, not to improve care. Regulators understand private equity, where the big money is made by flipping assets every 3-5 years. They understand the allure of private equity for you: a bigger paycheck, better reimbursements, and the potential for a big payment when the flip occurs. They understand antitrust, having fought it for decades in other sectors, and know that more consolidation of physician practices will result in higher and higher prices.

We’re at a critical juncture. Insurance companies have increased prior authorization requirements —and therefore your cost to practice medicine—by almost 24% compared to the pre-pandemic baseline. Have they increased your reimbursements to offset these ‘mandates’? Of course not. Something needed to give. Something gave.

What happens next? More consolidation. It’s happening as I write this.

Lucien W. Roberts, III is co-founder of Infusion Solutions and a mostly retired private practice administrator.

Related Videos